CMG Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio
CMG Pharmaceutical Co. Ltd cash flow-to-debt ratio. CMG Pharmaceutical Co. Ltd (058820) has a Cash Flow-to-Debt Ratio of -0.04x as of December 2025, meaning its operating cash flow of ₩-4.08 Billion could theoretically repay 0% of its total liabilities (₩104.41 Billion) in one year. Check CMG Pharmaceutical Co. Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of CMG Pharmaceutical Co. Ltd (2014–2025)
Cash flow-to-debt ratio of CMG Pharmaceutical Co. Ltd from 2014 to 2025. Historical debt coverage capacity for CMG Pharmaceutical Co. Ltd across 12 annual periods. Check total reinvestment intensity of CMG Pharmaceutical Co. Ltd to assess the company's total reinvestment commitment from operating cash flow.
CMG Pharmaceutical Co. Ltd Cash Flow-to-Debt Ratio by Year (2014–2025)
CMG Pharmaceutical Co. Ltd cash flow-to-debt ratio by year from 2014 to 2025. Year-by-year debt coverage analysis for CMG Pharmaceutical Co. Ltd. For the full cash flow conversion analysis, see 058820 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.11x | ₩-11.02 Billion | ₩104.41 Billion | ▼ -4244.1% |
| 2024 | 0.00x | ₩290.09 Million | ₩113.89 Billion | ▼ -96.6% |
| 2023 | 0.08x | ₩3.91 Billion | ₩51.87 Billion | ▼ -56.8% |
| 2022 | 0.17x | ₩4.94 Billion | ₩28.31 Billion | ▼ -55.2% |
| 2021 | 0.39x | ₩5.63 Billion | ₩14.47 Billion | ▲ +87.9% |
| 2020 | 0.21x | ₩2.94 Billion | ₩14.22 Billion | ▼ -11.4% |
| 2019 | 0.23x | ₩2.82 Billion | ₩12.08 Billion | ▲ +173.9% |
| 2018 | 0.09x | ₩886.78 Million | ₩10.40 Billion | ▼ -49.1% |
| 2017 | 0.17x | ₩1.95 Billion | ₩11.62 Billion | ▼ -28.3% |
| 2016 | 0.23x | ₩2.31 Billion | ₩9.87 Billion | ▼ -5.7% |
| 2015 | 0.25x | ₩2.41 Billion | ₩9.73 Billion | ▲ +210.0% |
| 2014 | 0.08x | ₩724.89 Million | ₩9.07 Billion | — |